An Integrative Methylation-Metabolism Gene Signature Defines Prognosis and Immunosuppression in Prostate Cancer
A genetic signature identifies prostate cancers resistant to immune therapy, guiding which patients might benefit from immunotherapy.
This study develops and validates a prostate cancer gene signature integrating DNA methylation and metabolic reprogramming markers, demonstrating superior prognostic stratification and immune evasion phenotype identification. The signature could guide immunotherapy patient selection and define actionable targets in the immunosuppressive prostate cancer microenvironment.
What the study was
- Study design
- Computational multi-omics analysis with clinical validation
- Population
- Prostate cancer patients with integrated methylation and metabolic gene expression data
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Chemical biology & drug design
Why it surfaced
Integrative epigenetic-metabolic prognostic signature in prostate cancer with immunosuppression context; relevant for precision immunotherapy selection in PCa.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.